Funding for this research was provided by:
Medical Research Council (MRC-DPFS gMR/L013215/1, Doctoral Training Account & MRC MR/N01042/1, MRC-DPFS MR/L013215/1, Clinician Scientist Fellowship G108/585)
Medical Research Council Clinical Sciences Centre
UCL, UCL Hospitals and UCLH/UCL Biomedical Research Centre
The Neurodis Foundation
Text and Data Mining valid from 2018-06-11
Received: 7 March 2018
Accepted: 8 May 2018
First Online: 11 June 2018
Ethics approval and consent to participate
: We confirm that Ethics Committee (Royal Marsden, reference number 09/H0801/79) and other regulatory approvals were obtained prior to initiation of the study, as detailed in [CitationRef removed, CitationRef removed]. All participants provided written, informed consent prior to participation.
: The initial study was supported in part by GE Healthcare Ltd., who developed the radiotracer, [Superscript removedF]GE-179. WT was an employee of GE Healthcare Ltd. CJM, JSD, and MJK have received fees from GE Healthcare Ltd. but have never been employees of the organisation. JSD has also received fees from UCB Pharma, Eisai, and GSK. The remaining authors declare that they have no competing interests.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.